within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AX23_Tenidap;

model Tenidap
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 1.277777777777778e-07,
    adminDuration = 600,
    adminMass = 120 / 1000000,
    adminCount = 1,
    Vd = 0.014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0045000000000000005,
    Tlag = 10.200000000000001,
    Vdp = 0.013,
    k12 = 1.0833333333333335e-07,
    k21 = 1.0833333333333335e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tenidap</td></tr><tr><td>ATC code:</td><td>M01AX23</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>120</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.46</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tenidap is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) and has both anti-inflammatory and disease-modifying properties. It was investigated primarily for the treatment of rheumatoid arthritis and osteoarthritis but was withdrawn in clinical development due to hepatotoxicity concerns. Tenidap is not approved or marketed today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01AX23 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tenidap;
